Comparable stake leader
WELLINGTON MANAGEMENT GROUP LLP
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001464521.
Comparable stake leader
WELLINGTON MANAGEMENT GROUP LLP
Disclosed value leader
WELLINGTON MANAGEMENT GROUP LLP
Comparable rows
50/50
Latest evidence
08 Jul 2026
Ownership snapshot
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Quick read
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
Company
|
14%
from 13D/G
|
$291,528,944
11,982,283 shares
|
— | 31 Mar 2026 |
| BCLS Fund III Investments, LP |
13D/G
3/4/5
10%+ Owner
|
12%
|
$282,936,119
10,448,158 shares
|
-$54,160,000 | 31 Mar 2026 |
| Hayfin Special Opportunities Fund II LP |
13D/G
Hayfin Management Holdings Limited
|
6.2%
|
$177,834,666
5,283,264 shares
|
$0 | 30 Sep 2025 |
| FMR LLC |
13D/G
13F
Company
|
5.7%
|
$159,219,679
4,730,234 shares
|
$0 | 30 Sep 2025 |
| HealthCor Partners Management LP |
13D/G
3/4/5
10%+ Owner
|
2.4%
|
$48,261,085
2,082,014 shares
|
-$106,988,264 | 24 Mar 2026 |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
Company · 10%+ Owner
|
9.8%
from 3/4/5
|
$254,203,684
10,448,158 shares
|
— | 31 Mar 2026 |
| Bain Capital Life Sciences Fund III, L.P. |
3/4/5
10%+ Owner
|
9.8%
|
$253,867,147
8,448,158 shares
|
-$58,898,336 | 28 Apr 2026 |
| Bain Capital Life Sciences III General Partner, LLC |
3/4/5
10%+ Owner
|
9.8%
|
$253,867,147
8,448,158 shares
|
-$58,898,336 | 28 Apr 2026 |
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Net insider flow leans to selling over the last 12 months. Net value: -$360,370,643.
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 8,854,474 | $0 | $259,513,199 | -$259,513,199 |
| 3-6 | 0 | 3,549,577 | $0 | $101,911,124 | -$101,911,124 |
| 6-9 | 40,000 | 0 | $1,053,680 | $0 | +$1,053,680 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Showing 1-17 of 17 reporting-owner rows connected to Heartflow, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| BCLS Fund III Investments, LP | 10%+ Owner | $253,867,147 | -$58,898,336 | -19% | Filing P/S | 28 Apr 2026 |
| BCLS Fund III Investments GP, LLC | 10%+ Owner | $253,867,147 | -$58,898,336 | -19% | Filing P/S | 28 Apr 2026 |
| Bain Capital Life Sciences III General Partner, LLC | 10%+ Owner | $253,867,147 | -$58,898,336 | -19% | Filing P/S | 28 Apr 2026 |
| Bain Capital Life Sciences Investors, LLC | 10%+ Owner | $253,867,147 | -$114,998,336 | -31% | Filing P/S | 28 Apr 2026 |
| Bain Capital Life Sciences Fund III, L.P. | 10%+ Owner | $253,867,147 | -$58,898,336 | -19% | Filing P/S | 28 Apr 2026 |
| Jeffrey C. Lightcap | Director | $217,828,174 | +$1,053,680 | +0.49% | Mixed | 16 Jun 2026 |
| John C.m. Farquhar | Chief Executive Officer, Director | $12,081,600 | -$5,044,039 | -29% | Filing P/S | 10 Jul 2026 |
| William C. Weldon | Director | $7,156,789 | Median | 08 Jul 2026 | ||
| Vikram Verghese | Chief Financial Officer | $6,847,251 | Median | 21 Jul 2026 | ||
| Campbell Rogers | Chief Medical Officer | $6,552,304 | -$5,341,992 | -45% | Mixed | 15 Jul 2026 |
| Timothy C. Barabe | Director | $5,522,697 | Median | 22 Jul 2026 | ||
| Marie L. Jones | Chief Accounting Officer | $756,249 | Mixed | 06 May 2026 | ||
| Julie A. Cullivan | Director | $682,275 | -$446,610 | -40% | Filing P/S | 16 Jun 2026 |
| HealthCor Partners Management LP | 10%+ Owner | $0 | Mixed | 11 Aug 2025 | ||
| Nicholas Downing | Director | Mixed | 07 Aug 2025 | |||
| Wayne Joseph Riley | Director | Mixed | 16 Jun 2026 | |||
| Casey M. Tansey | Director | Mixed | 16 Jun 2026 |
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Timothy C. Barabe | HTFL | Common Stock | Options Exercise | 2.01% | 3,710 | 188,231 | 22 Jul 2026 | Direct | ||
| Timothy C. Barabe | HTFL | Stock Option | Options Exercise | -19.8% | -3,710 | 15,000 | 22 Jul 2026 | Direct | ||
| Vikram Verghese | HTFL | Common Stock. | Options Exercise | 10.7% | 22,522 | 233,376 | 21 Jul 2026 | Direct | ||
| Vikram Verghese | HTFL | Stock Option | Options Exercise | -20.2% | -22,522 | 89,110 | 21 Jul 2026 | Direct | ||
| Timothy C. Barabe | HTFL | Common Stock | Options Exercise | 2.79% | 5,000 | 184,521 | 17 Jul 2026 | Direct | ||
| Timothy C. Barabe | HTFL | Stock Option | Options Exercise | -21.1% | -5,000 | 18,710 | 17 Jul 2026 | Direct | ||
| Campbell Rogers | HTFL | Common Stock | Sale | -9.41% | $237,113 | $25.72 | -9,219 | 88,731 | 15 Jul 2026 | Direct |
| Campbell Rogers | HTFL | Common Stock | Options Exercise | 10.4% | 9,219 | 97,950 | 15 Jul 2026 | Direct | ||
| Campbell Rogers | HTFL | Stock Options | Options Exercise | -9.09% | -9,219 | 92,191 | 15 Jul 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Sale | -4.93% | $626,096 | $27.75 | -22,562 | 435,373 | 10 Jul 2026 | Direct |
| William C. Weldon | HTFL | Common Stock | Options Exercise | 26.7% | 51,369 | 243,931 | 08 Jul 2026 | Direct | ||
| William C. Weldon | HTFL | Stock Option | Options Exercise | -100% | -17,123 | 0 | 08 Jul 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Sale | -7.83% | $1,361,500 | $35.00 | -38,900 | 457,935 | 24 Jun 2026 | Direct |
| William C. Weldon | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Timothy C. Barabe | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Julie A. Cullivan | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Jeffrey C. Lightcap | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Wayne Joseph Riley | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Casey M. Tansey | HTFL | Stock Option | Award | 16,075 | 16,075 | 16 Jun 2026 | Direct | |||
| Campbell Rogers | HTFL | Common Stock | Options Exercise | 12.7% | 10,000 | 88,731 | 15 Jun 2026 | Direct | ||
| Campbell Rogers | HTFL | Stock Option | Options Exercise | -12.2% | -10,000 | 71,633 | 15 Jun 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Sale | -4.34% | $643,017 | $28.50 | -22,562 | 496,835 | 10 Jun 2026 | Direct |
| Campbell Rogers | HTFL | Common Stock | Sale | -10.5% | $261,266 | $28.34 | -9,219 | 78,731 | 18 May 2026 | Direct |
| Campbell Rogers | HTFL | Common Stock | Options Exercise | 11.7% | 9,219 | 87,950 | 18 May 2026 | Direct | ||
| Campbell Rogers | HTFL | Stock Options | Options Exercise | -8.33% | -9,219 | 101,410 | 18 May 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Sale | -4.16% | $657,005 | $29.12 | -22,562 | 519,397 | 11 May 2026 | Direct |
| Marie L. Jones | HTFL | Common Stock. | Tax liability | -0.26% | -82 | 31,083 | 07 May 2026 | Direct | ||
| Campbell Rogers | HTFL | Common Stock | Tax liability | -0.8% | -637 | 78,731 | 07 May 2026 | Direct | ||
| Vikram Verghese | HTFL | Common Stock. | Tax liability | -0.22% | -473 | 210,854 | 07 May 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Tax liability | -0.35% | -1,904 | 541,959 | 07 May 2026 | Direct | ||
| Marie L. Jones | HTFL | Common Stock. | Tax liability | -1.53% | -485 | 31,165 | 06 May 2026 | Direct | ||
| Campbell Rogers | HTFL | Common Stock | Tax liability | -2.02% | -1,634 | 79,368 | 06 May 2026 | Direct | ||
| Vikram Verghese | HTFL | Common Stock. | Tax liability | -0.72% | -1,536 | 211,327 | 06 May 2026 | Direct | ||
| John C.m. Farquhar | HTFL | Common Stock | Tax liability | -0.97% | -5,300 | 543,863 | 06 May 2026 | Direct | ||
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -10.1% | $27,733,644 | $29.23 | -948,757 | 8,448,158 | 30 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -7.82% | $23,411,796 | $29.37 | -797,133 | 9,396,915 | 29 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| Bain Capital Life Sciences Investors, LLC | HTFL | Common Stock | Sale | -2.43% | $7,752,896 | $30.51 | -254,110 | 10,194,048 | 28 Apr 2026 | See footnotes |
| John C.m. Farquhar | HTFL | Common Stock | Sale | -3.95% | $602,857 | $26.72 | -22,562 | 549,163 | 10 Apr 2026 | Direct |